Therefore, the use of ASO against Bcl-2 (oblimersen) can also indirectly inhibit the transcription of CCND1a through the interaction between Bcl-2 and CCND1a, resulting in higher proliferation and invasive of mantle cell lymphoma. This evidence concerns the gene BCL2 and mantle cell lymphoma.